2023 NEJM) randomized 17,604 adults with overweight or obesity and established cardiovascular disease (without diabetes) to semaglutide 2.4 mg weekly or placebo
GLP-1 RA & Metformin Combination-Adverse Event Comparison Gender-stratified analysis revealed distinct temporal patterns in adverse event onset: Male patients predominantly experienced adverse events within the initial 30 days of treatment initiation, whereas female patients exhibited delayed onset, with the majority of adverse events emerging beyond 360 days of continuous therapy
[DOI] [PubMed] [Google Scholar] 206.DeFronzo RA, Inzucchi S, Abdul-Ghani M, Nissen SE
Important Ozempic lawsuit updates July 2026: The Ozempic MDL now has 3,848 pending cases
while Smoothie King launched a line of GLP-1 smoothies in autumn
A more convenient option A new obesity treatment comes as a standard pill